Resof

Скидка 5.00 usd
BRAND : RESOF PRICE : 225$ STRENGTH :400MG & 90MG ACTIVE INGERIDENTS: RESOF-SOFOSBUVIR-400MG COMPANY NAME : DR.REDDYS TABLETS COUNT : 28 TABLETS read more

225.00 usd
230.00
- +
Share

DESCRIPTION

RESOF (SOFOSBUVIR 400MG) 

Resof (Sofosbuvir 400mg) is a prescription medicine used with other antiviral medicines to treat adults with chronic hepatitis C (Hep C) with or without cirrhosis (compensated). Resof recommended with some combination of ribavirin, peginterferon-alfa, simeprevir, ledipasvir, daclatasvir, or velpatasvir to cure genotype 1 to 6 infections. Cure rates are 30 to 97% depending on the type of hepatitis C virus involved. Resof is safe and effective in patient who have had a liver transplant.

Resof (Sofosbuvir 400mg) is activated in the liver to the triphosphate GS-461203 by hydrolysis of the carboxylate ester by either of the enzymes cathepsin A or carboxylesterase 1, followed by cleaving of the phosphoramidate by the enzyme histidine triad nucleotide-binding protein 1 (HINT1), and subsequent repeated phosphorylation. Dephosphorylation creates the inactive metabolite GS-331077. The half life of Resof is 0.4 hours, and the half life of GS-331007 is 27 hours. 

Following a single 400 mg oral dose of Resof , 80% is excreted in urine, 14% in feces, and 2.5% in expired air recovery. However, of the urine recovery 78% was the metabolite (GS-331007) and 3.5% was Resof.

Resof (Sofosbuvir 400mg) has a number of ideal properties, once daily dosing, no meal restrictions, few adverse effects, minimal drug-drug interactions, high genetic barrier to resistance, good safety and efficacy in patients with advanced liver disease, and excellent sustained virologic response rates in patients with unfavorable baseline characteristics
Resof (Sofosbuvir 400mg) (in combination with ledipasvir, daclatasvir or simeprevir) should not be used with amiodarone due to the risk of abnormally slow heartbeats. 

Resof (Sofosbuvir 400mg) is a substrate of P-glycoprotein, a transporter protein that pumps drugs and other substances from intestinal epithelium cells back into the gut. Therefore, inducers of intestinal P-glycoprotein, such as rifampicin and St. John's wort, could reduce the absorption of Hepcinat. 
In addition, coadministration of Resof with anticonvulsants (carbamazepine, phenytoin, phenobarbital, oxcarbazepine), antimycobacterials (rifampin, rifabutin, rifapentine), and the HIV protease inhibitor tipranavir and ritonavir is expected to decrease Resof concentration. Thus, coadministration is not recommended. 

The interaction between Resof and a number of other drugs, such as ciclosporin, darunavir/ritonavir, efavirenz, emtricitabine, methadone, raltegravir, rilpivirine, tacrolimus, or tenofovir disoproxil, were evaluated in clinical trials and no dose adjustment is needed for any of these drugs. 

Common side effects include feeling tired, headache, nausea, and trouble sleeping. Side effects are generally more common in interferon-containing regimens. Resof may reactivate hepatitis B in those who have been previously infected. In combination with ledipasvir, daclatasvir or simeprevir it is not recommended with amiodarone due to the risk of an abnormally slow heartbeat. 
    No comments yet
Write a comment
Your name
Your name
Captcha

Sale of day

Choice of buyers. Only popular options!Choice of buyers.
Only popular options!

view all
  • Hepatitis C
    Hepatitis C is a liver disease caused by the hepatitis C virus: this virus can cause both acute and chronic hepatitis infection, which varies in severity from mild illness, lasting several weeks, to a serious lifelong disease.